These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34796851)

  • 21. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.
    de Wolff L; van Nimwegen JF; Mossel E; van Zuiden GS; Stel AJ; Majoor KI; Olie L; Los LI; Vissink A; Spijkervet FKL; Verstappen GMPJ; Kroese FGM; Arends S; Bootsma H
    Semin Arthritis Rheum; 2022 Apr; 53():151955. PubMed ID: 35091325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.
    Serrano EV; Valim V; Miyamoto ST; Giovelli RA; Paganotti MA; Cadê NV
    Rev Bras Reumatol; 2013; 53(6):483-93. PubMed ID: 24477727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
    Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
    PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?
    Devauchelle-Pensec V; Gottenberg JE; Jousse-Joulin S; Berthelot JM; Perdriger A; Hachulla E; Hatron PY; Puechal X; Le Guern V; Sibilia J; Chiche L; Goeb V; Vittecoq O; Larroche C; Fauchais AL; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Dieudé P; Pers JO; Cornec D; Seror R; Mariette X; Nowak E; Saraux A
    PLoS One; 2015; 10(9):e0133907. PubMed ID: 26368934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies.
    Acar-Denizli N; Horváth IF; Mandl T; Priori R; Vissink A; Hernandez-Molina G; Armagan B; Praprotnik S; Sebastian A; Bartoloni E; Rischmueller M; Pasoto SG; Nordmark G; Nakamura H; Fernandes Moça Trevisani V; Retamozo S; Carsons SE; Maure-Noia B; Sánchez-Berná I; López-Dupla M; Fonseca-Aizpuru E; Melchor Díaz S; Vázquez M; Díaz Cuiza PE; de Miguel Campo B; Ng WF; Rasmussen A; Dong X; Li X; Baldini C; Seror R; Gottenberg JE; Kruize AA; Sandhya P; Gandolfo S; Kwok SK; Kvarnstrom M; Solans R; Sene D; Suzuki Y; Isenberg DA; Valim V; Hofauer B; Giacomelli R; Devauchelle-Pensec V; Atzeni F; Gheita TA; Morel J; Izzo R; Kalyoncu U; Szántó A; Olsson P; Bootsma H; Ramos-Casals M; Kostov B; Brito-Zerón P;
    Clin Exp Rheumatol; 2020; 38 Suppl 126(4):85-94. PubMed ID: 33095152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome.
    Moerman RV; Arends S; Meiners PM; Vissink A; Spijkervet FK; Kroese FG; Brouwer E; Bootsma H
    J Rheumatol; 2017 Mar; 44(3):292-296. PubMed ID: 28089983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).
    van Nimwegen JF; Mossel E; van Zuiden GS; Wijnsma RF; Delli K; Stel AJ; van der Vegt B; Haacke EA; Olie L; Los LI; Verstappen GM; Pringle SA; Spijkervet FKL; Kroese FGM; Vissink A; Arends S; Bootsma H
    Lancet Rheumatol; 2020 Mar; 2(3):e153-e163. PubMed ID: 38263653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
    Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
    Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
    Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
    Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
    Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
    Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
    Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
    Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S;
    BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
    Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
    Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q; Wang S; Jiang H; Liu L
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [No Abstract]   [Full Text] [Related]  

  • 38. Ten years of the ESSDAI: is it fit for purpose?
    de Wolff L; Arends S; van Nimwegen JF; Bootsma H
    Clin Exp Rheumatol; 2020; 38 Suppl 126(4):283-290. PubMed ID: 33095151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting.
    Pavlych V; Di Muzio C; Alunno A; Carubbi F
    Front Med (Lausanne); 2020; 7():534. PubMed ID: 33015092
    [No Abstract]   [Full Text] [Related]  

  • 40. Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.
    Seror R; Baron G; Camus M; Cornec D; Perrodeau E; Bowman SJ; Bombardieri M; Bootsma H; Gottenberg JE; Fisher B; Hueber W; van Roon JA; Devauchelle-Pensec V; Gergely P; Mariette X; Porcher R; ;
    Ann Rheum Dis; 2022 Jul; 81(7):979-989. PubMed ID: 35393271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.